For CBF‐AML, the anti‐CD33 monoclonal antibody, GO, has shown benefit when added to 7+3 induction therapy for patients with favorable or intermediate‐risk cytogenetics [28]. This evidence concerns the gene CEBPZ and acute myeloid leukemia.